Predictions
Apollo Medical Holdings, Inc.
Start price
Target price
Perf. (%)
€38.80
26.02.24
26.02.24
€46.04
26.02.25
26.02.25
-1.03%
18.04.24
18.04.24
Adtalem Global Education Inc
Start price
Target price
Perf. (%)
€43.40
26.02.24
26.02.24
€44.20
26.02.25
26.02.25
-0.46%
18.04.24
18.04.24
Lifeway Foods Inc.
Start price
Target price
Perf. (%)
€11.10
26.02.24
26.02.24
€12.89
26.02.25
26.02.25
68.47%
18.04.24
18.04.24
HelloFresh SE
Start price
Target price
Perf. (%)
€12.70
23.02.24
23.02.24
€13.00
23.02.25
23.02.25
3.86%
29.02.24
29.02.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Keurig Dr. Pepper Inc.
Start price
Target price
Perf. (%)
€27.89
23.02.24
23.02.24
€37.87
23.02.25
23.02.25
5.84%
18:08
18:08
Keurig Dr. Pepper Inc.
Start price
Target price
Perf. (%)
€27.90
23.02.24
23.02.24
€31.42
23.02.25
23.02.25
5.78%
18:08
18:08
International Flavors & Fragrances Inc.
Start price
Target price
Perf. (%)
€72.70
22.02.24
22.02.24
€83.21
22.02.25
22.02.25
8.65%
15:52
15:52
International Flavors & Fragrances Inc.
Start price
Target price
Perf. (%)
€72.70
22.02.24
22.02.24
€78.58
22.02.25
22.02.25
8.65%
15:52
15:52
Apollo Medical Holdings, Inc.
Start price
Target price
Perf. (%)
€38.40
22.02.24
22.02.24
€50.85
22.02.25
22.02.25
0.00%
18.04.24
18.04.24
Walgreens Boots Alliance Inc.
Start price
Target price
Perf. (%)
€20.33
20.02.24
20.02.24
€18.48
20.02.25
20.02.25
-17.44%
17:47
17:47
US Foods Holding Corp
Start price
Target price
Perf. (%)
€46.00
20.02.24
20.02.24
€52.66
20.02.25
20.02.25
5.65%
16.04.24
16.04.24
US Foods Holding Corp
Start price
Target price
Perf. (%)
€46.60
20.02.24
20.02.24
€59.12
20.02.25
20.02.25
4.29%
16.04.24
16.04.24
US Foods Holding Corp
Start price
Target price
Perf. (%)
€46.60
20.02.24
20.02.24
€54.50
20.02.25
20.02.25
4.29%
16.04.24
16.04.24
HelloFresh SE
Start price
Target price
Perf. (%)
€12.05
20.02.24
20.02.24
€14.00
20.02.25
20.02.25
5.35%
23.02.24
23.02.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation